Dry Eye Clinical Trial
Official title:
An Interventional, Non-comparative, Single-center Post Marketing Clinical Follow-up (PMCF) Study to Evaluate Performance and Safety of "Optrex Double Action Soothing and Lubricating Drops"
NCT number | NCT05824000 |
Other study ID # | COC-R6-CBM |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 7, 2022 |
Est. completion date | August 5, 2022 |
Verified date | May 2023 |
Source | C.O.C. Farmaceutici S.r.l. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Allergic conjunctivitis (or ocular allergy) and dry eye disease (DED) are two major ocular surface disorders affecting millions of people. A typical clinical symptom of allergic conjunctivitis is itching which is also observed in subjects suffering from DED. Common symptoms of DED also include a foreign body sensation, dryness, irritation, burning sensation and visual disturbance. Patients with allergic conjunctivitis or moderate-to-severe DED may experience a reduced quality of life due to ocular pain, difficulty in performing daily activities, and depression. Gel-based artificial tear supplements may offer longer retention times and act as a supplement to the mucin layer. Carbomer (also known as Carbopol polymers) is awater-soluble polymeric resin that exhibit excellent viscoelastic and mucoadhesive properties when compared with other polymers. Carbomer is used in liquid or semisolid pharmaceutical, cosmetics, and ophthalmic formulations as rheology modifiers. Aqueous carbomer gels have been used for the treatment of dry eye and allergic conjunctivitis as they provide prolonged ocular residence time of conventional ophthalmic solutions. Furthermore, carbomer has shown compatibility with many active ingredients, good thermal stability, excellent organoleptic characteristics, and good patient acceptance. For these reasons, an interventional, non-comparative, single-center Post Marketing Clinical Follow-up (PMCF) study was planned to evaluate the performance and safety of "Optrex Double Action soothing and lubricating drops" for itchy and watery eyes. The objectives of the PMCF study are confirmation of the performance, collection of additional safety data regarding expected adverse events and detection of potential unexpected adverse events associated with the use of "Optrex Double Action soothing and lubricating drops" according to the Instructions for Use (IFU). Each subject, after signing the Informed Consent Form, will enter the screening and baseline phase (the 2 visits will coincide) during which baseline procedures will be completed. At baseline visit, "Optrex Double Action soothing and lubricating drops" will be prescribed to the enrolled subject. The patient will perform 2 on-site visits: V0 and V2/EOS. To monitor the safety, 1 phone contact is planned (V1) to check for potential adverse events and concomitant medications intake.
Status | Completed |
Enrollment | 20 |
Est. completion date | August 5, 2022 |
Est. primary completion date | August 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient Informed consent form (ICF) signed; - Male and Female Aged = 18 years at the time of the signature of the ICF; - Patients with ocular conditions typically associated with itchy and watery eyes (e.g. allergic conjunctivitis, dry eye disease); - Willing not to use other eye drops during the entire treatment period. Exclusion Criteria: - Other - different - eyes clinical conditions (e.g. glaucoma); - Suspected alcohol or drug abuse. - Known hypersensitivity or allergy to Investigational Product (IP) components; - Other clinically significant and uncontrolled pathologies that may interfere with study results (e.g. rheumatic disease, diabetes); - Participation in another investigational study; - Inability to follow all study procedures, including attending all site visits, tests and examinations; - Mental incapacity that precludes adequate understanding or cooperation. |
Country | Name | City | State |
---|---|---|---|
Italy | Azienda Ospedaliera Policlinico Mater Domini - Università Magna Grecia di Catanzaro | Catanzaro | CZ |
Lead Sponsor | Collaborator |
---|---|
C.O.C. Farmaceutici S.r.l. |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Schirmer I test: to evaluate the performance of "Optrex Double Action soothing and lubricating drops" as soothing and lubricating eye drops for itchy and watery eyes, through the Schirmer I test | From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2) | ||
Secondary | Change in Ocular Surface Disease Index (OSDI): to evaluate the performance of "Optrex Double Action soothing and lubricating drops" used to provide relief from eye discomfort associated with itchy and watery eyes, through OSDI | From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2) | ||
Secondary | To evaluate the safety and tolerability of "Optrex Double Action soothing and lubricating drops" through Visual Analogue Scale (VAS) - evaluation of symptoms related to dry eye disease (burning, fatigue, discomfort, redness) | Visual Analogue Scale:
Minimum value = 0; Maximum value = 10; Higher scores mean a better outcome. |
End of study visit (EOS/V2 = Day 30 ± 2) | |
Secondary | To evaluate the patient satisfaction through a Rensis Likert 5 points patient satisfaction scale | Rensis Likert 5 points patient satisfaction scale Minimum value: Very dissatisfied Maximum value: Vert satisfied Higher scores mean a better outcome | End of study visit (EOS/V2 = Day 30 ± 2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |